Table 2.
Summary of clinical studies on surface-modified membranes for hemodialysis.
Membrane | Surface Modification | Main Findings | Refs. |
---|---|---|---|
Asymmetric triacetate (ATA) | Smoother surface of parent polymer symmetric cellulose triacetate |
|
Cross-over study [46] Cross-over studies [47,50] Randomized cross-over studies [49,51] |
Polymethylmethacrylate NF | Reduction in negative charges of parent polymer polymethylmethacrylate |
|
Cross-over study [54] Randomized study [55] |
Hydrolink NV | Application of a hydrophilic polymer onto the inner surface of PSF material |
|
Prospective sequential study [59] Randomized study [60] Randomized study [63] Stratified-randomized study [65] Randomized study [72] Retrospective study [73] |
Surface modifying molecule-modified membrane | Incorporation of surface modifying molecule 1 into PSF dialyzer fibers |
|
Prospective sequential study [75] |
Heparin-coated membrane | Binding of heparin on the blood side of polyacrylonitrile sodium methallylsulfonate copolymer coated with polyethyleneimine before heparin grafting |
|
Observational studies [81,82] Randomized controlled studies [83,84,87] Randomized cross-over studies [85,86] Randomized controlled study [90] |
Vitamin E-coated membrane | Coating with vitamin E (alpha-tocopherol) on the blood surface of membrane |
|
Meta-analysis [103] Meta-analysis [103] Randomized controlled cross-over study [110] Meta-analysis [103] Randomized controlled study [114] Randomized cross-over study [85] |
HD—hemodialysis; PSF—polysulfone; ESA—erythropoiesis stimulating agent.